Novartis gains exclusive rights to Debio 025
- Details
- Category: Novartis
Novartis has gained exclusive rights to develop and market Debio 025 (alisporivir), a potential first-in-class antiviral agent currently in Phase IIb development for the treatment of hepatitis C.
US FDA Approves New Indication for Crestor (Rosuvastatin Calcium)
- Details
- Category: AstraZeneca
AstraZeneca announced that the US Food and Drug Administration (FDA) has approved CRESTOR (rosuvastatin calcium) to reduce the risk of stroke, myocardial infarction (heart attack) and arterial revascularization procedures in individuals without clinically evident coronary heart disease but with an increased risk of cardiovascular disease (CVD)
Denosumab Trial met Primary and all Secondary Endpoints
- Details
- Category: Amgen
Amgen (Nasdaq: AMGN) has announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 1,901 men with advanced prostate cancer met its primary and secondary endpoints.
Pfizer and Keas Partner to Help Consumers Take a More Active Role in Their Health and Wellness
- Details
- Category: Pfizer
Pfizer and Keas announced today they have entered into an alliance to collaborate on the Keas platform to enable Health and Wellness experts to author, sell and distribute personalized online Care Plans directly to patients.
GSK launches new specialist unit to research and develop medicines for rare diseases
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) has announced the formation of a new standalone unit specialising in the development and commercialisation of medicines for rare diseases. Over 5,500 rare diseases have been identified(1) of which less than 10% are currently being treated(2), presenting a significant unmet medical need.
Strong operating performance for Roche in 2009
- Details
- Category: Roche
The total Roche Group's sales grew by 10% in local currencies (8% in Swiss francs; 7% in US dollars) to 49.1 billion Swiss francs, with the Pharmaceuticals Division accounting for 80% of Group sales and the Diagnostics Division contributing 20%. Sales growth in both divisions exceeded market growth.
Pfizer Reports Fourth-Quarter and Full-Year 2009 Results
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) today reported financial results for fourth-quarter and full-year 2009. On October 15, 2009, Pfizer completed the acquisition of Wyeth and, consequently, fourth-quarter and full-year 2009 results include the legacy Wyeth operations from the acquisition date through Pfizer's domestic and international year-ends.
More Pharma News ...
- VYVANSE® - new ADHD treatment option - now available in Canada
- Roche establishes new medical research hub in Singapore
- Lilly Reports Fourth-Quarter and Full-Year 2009 Results
- AstraZeneca Fourth Quarter and Full Year Results 2009
- New Pfizer Pipeline Shows Progress And Growth In Vaccines, Biologics And High-Priority Disease Areas
- Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter
- Novartis achieves record results in 2009